Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361953212> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4361953212 abstract "<div>AbstractPurpose:<p>DNA mismatch repair (MMR) deficiency is a hallmark of Lynch syndrome, the most common inherited cancer syndrome. MMR-deficient cancer cells accumulate numerous insertion/deletion mutations at microsatellites. Mutations of coding microsatellites (cMS) lead to the generation of immunogenic frameshift peptide (FSP) neoantigens. As the evolution of MMR-deficient cancers is triggered by mutations inactivating defined cMS-containing tumor suppressor genes, distinct FSP neoantigens are shared by most MMR-deficient cancers. To evaluate safety and immunogenicity of an FSP-based vaccine, we performed a clinical phase I/IIa trial (Micoryx).</p>Patients and Methods:<p>The trial comprised three cycles of four subcutaneous vaccinations (FSP neoantigens derived from mutant <i>AIM2, HT001, TAF1B</i> genes) mixed with Montanide ISA-51 VG over 6 months. Inclusion criteria were history of MMR-deficient colorectal cancer (UICC stage III or IV) and completion of chemotherapy. Phase I evaluated safety and toxicity as primary endpoint (six patients), phase IIa addressed cellular and humoral immune responses (16 patients).</p>Results:<p>Vaccine-induced humoral and cellular immune responses were observed in all patients vaccinated per protocol. Three patients developed grade 2 local injection site reactions. No vaccination-induced severe adverse events occurred. One heavily pretreated patient with bulky metastases showed stable disease and stable CEA levels over 7 months.</p>Conclusions:<p>FSP neoantigen vaccination is systemically well tolerated and consistently induces humoral and cellular immune responses, thus representing a promising novel approach for treatment and even prevention of MMR-deficient cancer.</p></div>" @default.
- W4361953212 created "2023-04-05" @default.
- W4361953212 creator A5003615636 @default.
- W4361953212 creator A5007438121 @default.
- W4361953212 creator A5017287655 @default.
- W4361953212 creator A5024936471 @default.
- W4361953212 creator A5054910113 @default.
- W4361953212 creator A5060553987 @default.
- W4361953212 creator A5061570687 @default.
- W4361953212 creator A5079885079 @default.
- W4361953212 creator A5086063124 @default.
- W4361953212 date "2023-03-31" @default.
- W4361953212 modified "2023-09-26" @default.
- W4361953212 title "Data from A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial" @default.
- W4361953212 doi "https://doi.org/10.1158/1078-0432.c.6529529.v1" @default.
- W4361953212 hasPublicationYear "2023" @default.
- W4361953212 type Work @default.
- W4361953212 citedByCount "0" @default.
- W4361953212 crossrefType "posted-content" @default.
- W4361953212 hasAuthorship W4361953212A5003615636 @default.
- W4361953212 hasAuthorship W4361953212A5007438121 @default.
- W4361953212 hasAuthorship W4361953212A5017287655 @default.
- W4361953212 hasAuthorship W4361953212A5024936471 @default.
- W4361953212 hasAuthorship W4361953212A5054910113 @default.
- W4361953212 hasAuthorship W4361953212A5060553987 @default.
- W4361953212 hasAuthorship W4361953212A5061570687 @default.
- W4361953212 hasAuthorship W4361953212A5079885079 @default.
- W4361953212 hasAuthorship W4361953212A5086063124 @default.
- W4361953212 hasBestOaLocation W43619532122 @default.
- W4361953212 hasConcept C104317684 @default.
- W4361953212 hasConcept C121608353 @default.
- W4361953212 hasConcept C126322002 @default.
- W4361953212 hasConcept C203014093 @default.
- W4361953212 hasConcept C2776559941 @default.
- W4361953212 hasConcept C2780868878 @default.
- W4361953212 hasConcept C29906990 @default.
- W4361953212 hasConcept C501734568 @default.
- W4361953212 hasConcept C502942594 @default.
- W4361953212 hasConcept C526805850 @default.
- W4361953212 hasConcept C55493867 @default.
- W4361953212 hasConcept C60748783 @default.
- W4361953212 hasConcept C71924100 @default.
- W4361953212 hasConcept C86803240 @default.
- W4361953212 hasConcept C8891405 @default.
- W4361953212 hasConceptScore W4361953212C104317684 @default.
- W4361953212 hasConceptScore W4361953212C121608353 @default.
- W4361953212 hasConceptScore W4361953212C126322002 @default.
- W4361953212 hasConceptScore W4361953212C203014093 @default.
- W4361953212 hasConceptScore W4361953212C2776559941 @default.
- W4361953212 hasConceptScore W4361953212C2780868878 @default.
- W4361953212 hasConceptScore W4361953212C29906990 @default.
- W4361953212 hasConceptScore W4361953212C501734568 @default.
- W4361953212 hasConceptScore W4361953212C502942594 @default.
- W4361953212 hasConceptScore W4361953212C526805850 @default.
- W4361953212 hasConceptScore W4361953212C55493867 @default.
- W4361953212 hasConceptScore W4361953212C60748783 @default.
- W4361953212 hasConceptScore W4361953212C71924100 @default.
- W4361953212 hasConceptScore W4361953212C86803240 @default.
- W4361953212 hasConceptScore W4361953212C8891405 @default.
- W4361953212 hasLocation W43619532121 @default.
- W4361953212 hasLocation W43619532122 @default.
- W4361953212 hasOpenAccess W4361953212 @default.
- W4361953212 hasPrimaryLocation W43619532121 @default.
- W4361953212 hasRelatedWork W1981827577 @default.
- W4361953212 hasRelatedWork W2010057931 @default.
- W4361953212 hasRelatedWork W2039302924 @default.
- W4361953212 hasRelatedWork W2168733106 @default.
- W4361953212 hasRelatedWork W2294957859 @default.
- W4361953212 hasRelatedWork W2330029074 @default.
- W4361953212 hasRelatedWork W2347173399 @default.
- W4361953212 hasRelatedWork W2411114470 @default.
- W4361953212 hasRelatedWork W2887228165 @default.
- W4361953212 hasRelatedWork W3089414716 @default.
- W4361953212 isParatext "false" @default.
- W4361953212 isRetracted "false" @default.
- W4361953212 workType "article" @default.